Evidence that GLUT-2 mRNA and protein concentrations are decreased by hyperinsulinaemia and increased by hyperglycaemia in liver of diabetic rats

R Burcelin, M Eddouks, J Kande, R Assan, J Girard, R Burcelin, M Eddouks, J Kande, R Assan, J Girard

Abstract

GLUT-2, glucokinase (GK) and phosphoenolpyruvate carboxykinase (PEPCK) mRNA expression was studied in the liver of chronically catheterized diabetic rats during the 3 days after an intravenous injection of 65 mg of streptozotocin (STZ)/kg. At 6 h after the STZ injection, portal plasma insulin levels were 270 +/- 32 mu-units/ml and blood glucose was 1.4 +/- 0.4 mmol/l, owing to pancreatic beta-cell destruction. GLUT-2 and PEPCK mRNA concentrations were rapidly and dramatically decreased (> 90%), whereas GK mRNA was increased. After 30 h, plasma insulin concentrations were lower than 5 mu-units/ml and blood glucose was > 20 mmol/l. GLUT-2 and PEPCK mRNA concentrations increased 2-fold and GK mRNA disappeared progressively. In order to assess the relative roles of hyperglycaemia and insulinopenia, blood glucose was clamped at 6.4 +/- 0.5 mmol/l from 18 to 72 h after STZ injection by phlorizin infusion (0.5-2 g/day per kg) or at 6.6 +/- 0.3 mmol/l from 18 to 48 h after STZ injection by insulin infusion (0.25 unit/min per kg). GLUT-2 mRNA concentrations were 50% lower in phlorizin-infused than in untreated diabetic rats. The low levels of GK mRNA and the high levels of PEPCK mRNA were unaffected by normalization of hyperglycaemia in phlorizin-infused diabetic rats. In insulin-infused rats (portal plasma insulin levels of 40 mu-units/ml) GLUT-2 mRNA levels were 25% of those in untreated diabetic rats, and they increased rapidly 6 h after insulin infusion was stopped. Liver GLUT-2 protein concentration showed similar changes in response to STZ injection and to phlorizin or insulin treatment, but after a delay of several hours. From this work we conclude that GLUT-2 gene expression is dramatically and rapidly (< 6 h) decreased by portal hyperinsulinaemia and increased by hyperglycaemia.

References

    1. J Clin Invest. 1990 Aug;86(2):542-7
    1. Diabetes. 1990 Apr;39(4):441-6
    1. J Clin Invest. 1989 Aug;84(2):404-11
    1. Cell. 1988 Oct 21;55(2):281-90
    1. J Biol Chem. 1987 May 5;262(13):6032-8
    1. Nature. 1970 Aug 15;227(5259):680-5
    1. J Biol Chem. 1981 Oct 25;256(20):10224-7
    1. Science. 1989 Jul 7;245(4913):60-3
    1. Nature. 1989 Jul 6;340(6228):70-2
    1. J Biol Chem. 1988 Jan 15;263(2):740-4
    1. Annu Rev Biochem. 1986;55:1059-89
    1. J Clin Invest. 1973 Dec;52(12):3190-200
    1. Am J Physiol. 1968 Nov;215(5):1200-9
    1. J Biol Chem. 1983 Aug 10;258(15):9143-6
    1. J Biol Chem. 1982 Jul 10;257(13):7629-36
    1. J Biol Chem. 1984 Jan 10;259(1):224-30
    1. Diabetes. 1984 Apr;33(4):328-32
    1. J Biol Chem. 1984 Jan 10;259(1):343-6
    1. Eur J Biochem. 1991 Dec 18;202(3):985-91
    1. Diabetes. 1992 Jan;41(1):22-5
    1. Biochem Biophys Res Commun. 1991 Mar 29;175(3):995-1002
    1. Diabetes. 1990 Jun;39(6):712-9
    1. Biochem J. 1990 Nov 1;271(3):585-9
    1. Anal Biochem. 1987 Apr;162(1):156-9
    1. Nature. 1989 Jul 6;340(6228):72-4
    1. J Biol Chem. 1989 Dec 25;264(36):21824-9
    1. Eur J Biochem. 1977 Apr 1;74(2):397-403
    1. Recent Prog Horm Res. 1991;47:349-87; discussion 387-8

Source: PubMed

3
Suscribir